Astrocyte Pharmaceuticals

Edit info

Founded: 2014

Location: Cambridge, MA

Employee range: 1 - 10

Clinical stage: Clin1b

Therapy area: Ischemic stroke

Drug types: NEU, X_X, CVV, PN

Lead product: AST-004

Funding: $6M B Aug 2023

Investors: Dreavent Capital, Alzheimer's Drug Discovery Foundation

astrocytepharma.com

linkedin.com

Drug notes:

Also Clin1 TBI, Clin0 concussion, RD/Clin0 Alzheimer's; AST-008 RD/Clin0 pain, migraine; undisclosed RD/Clin0 CNS conditions

About:

Astrocyte Pharmaceuticals uses astrocytes to develop neuroprotective therapies for treatment of traumatic brain injuries, concussions, stroke, and neurodegenerative disease. Astrocytes and other glial cells play vital functions in brain cell maintenance and repair, making them great therapeutic targets. Astrocyte Pharma is a clinical-stage biopharma company. Co-founders William S. Korinek and James D. Lechleiter started Astrocyte Pharma in 2014.

Jobs:

Main

Contact: recruit@workinbiotech.com